Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 3/2013

01-06-2013 | Original Paper

Chromatin changes in papillary thyroid carcinomas may predict patient outcome

Authors: R. C. Ferreira, L. L. Cunha, P. S. Matos, R. L. Adam, F. Soares, J. Vassallo, L. S. Ward

Published in: Cellular Oncology | Issue 3/2013

Login to get access

Abstract

Purpose

New insights in prognostic predictions are urgently needed for papillary thyroid carcinoma (PTC). The present study aimed to investigate whether computerized analysis of chromatin texture allows the identification of PTC patients with a poor prognosis.

Methods

We randomnly selected paraffin-embedded blocks from surgical specimens of 103 classic cases of PTC. During follow-up, 68 of the patients were classified as free of disease, whereas 35 presented with recurrences. Characteristics of chromatin were obtained from digitized images of at least 100 randomly selected tumor nuclei per patient. An independent series of 30 goiters was used to validate our observations.

Results

Stage, age and distant metastases were found to serve as independent prognostic factors for survival. In addition, multivariate Cox regression confirmed variable cluster prominence as an independent prognostic factor. By comparing malignant and benign nodules, we found that the PTC lesions presented with higher nuclear perimeters, nuclear areas, Minkowski fractal dimensions, optical densities and nuclear longest chords.

Conclusion

From our results we conclude that, in conjunction with clinical and histopathological data, morphometric data may provide relevant prognostic information in PTC patients.
Literature
1.
R. Siegel, D. Naishadham, A. Jemal, Cancer statistics, 2012. CA Canc. J. Clin. 62, 10–29 (2012)CrossRef
2.
J.D. Cramer, P. Fu, K.C. Harth, S. Margevicius, S.M. Wilhelm, Analysis of the rising incidence of thyroid cancer using the surveillance, epidemiology and end results national cancer data registry. Surgery 148, 1147–1152 (2010). discussion 52–3PubMedCrossRef
3.
M.R. Pelizzo, I. Merante Boschin, A. Toniato, C. Pagetta, E. Casal Ide, C. Mian, D. Rubello, Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. Minerv. Endocrinol. 33, 359–379 (2008)
4.
R. Ghossein, Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin. Arch. Pathol. Lab. Med. 133, 683–691 (2009)PubMed
5.
N. American Thyroid Association Guidelines Taskforce on Thyroid, C. Differentiated Thyroid, D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 19, 1167–214 (2009)
6.
A. Knezevic-Obad, I. Knezevic Stromar, Cytomorphological characteristics of thyroid papillary carcinoma and their prognostic value. Acta. Med. Croat. 62, 365–371 (2008)
7.
S.R. Shih, H.Y. Li, Y.L. Hsiao, T.C. Chang, Prognostic significance of cytologic features in fine-needle aspiration cytology samples of papillary thyroid carcinoma: preliminary report. Thyroid 16, 775–780 (2006)PubMedCrossRef
8.
L.J. Layfield, E.S. Cibas, Z. Baloch, Thyroid fine needle aspiration cytology: a review of the National Cancer Institute state of the science symposium. Cytopathology 21, 75–85 (2010)PubMedCrossRef
9.
G.J. Price, W.G. McCluggage, M.M. Morrison, G. McClean, L. Venkatraman, J. Diamond, H. Bharucha, R. Montironi, P.H. Bartels, D. Thompson, P.W. Hamilton, Computerized diagnostic decision support system for the classification of preinvasive cervical squamous lesions. Hum. Pathol. 34, 1193–1203 (2003)PubMedCrossRef
10.
R. De Marchi Triglia, K. Metze, L.C. Zeferino, L.A. Lucci De Angelo Andrade, HPV in situ hybridization signal patterns as a marker for cervical intraepithelial neoplasia progression. Gynecol. Oncol. 112, 114–118 (2009)PubMedCrossRef
11.
R.C. Ferreira, P.S. de Matos, R.L. Adam, N.J. Leite, K. Metze, Application of the Minkowski-Bouligand fractal dimension for the differential diagnosis of thyroid follicular neoplasias. Cell. Oncol. 28, 331–333 (2006)PubMed
12.
R.C. Ferreira, L.S. Ward, R.L. Adam, N.J. Leite, K. Metze, P.S. Matos, Contribution of nuclear texture analysis for the differential diagnosis of follicular lesions of the thyroid: comparison to immunohistochemical markers. Arq. Bras. Endocrinol. Metabol. 53, 804–810 (2009)PubMedCrossRef
13.
V. Bedin, R.L. Adam, B.C. de Sa, G. Landman, K. Metze, Fractal dimension of chromatin is an independent prognostic factor for survival in melanoma. BMC. Canc. 10, 260 (2010)CrossRef
14.
K. Metze, R.C. Ferreira, R.L. Adam, Classification of thyroid follicular lesions based on nuclear texture features–lesion size matters. Cytometr. A. 77, 1101–1102 (2010)CrossRef
15.
A.G. Nikonenko, Y.M. Bozhok, Patterns of papillary thyroid carcinoma cells analyzed in fine-needle aspiration smears may reveal changes in tumor cell behavior. Diagn. Cytopathol. 40(Suppl 1), E55–E61 (2012)PubMedCrossRef
16.
F. Pitoia, L. Ward, N. Wohllk, C. Friguglietti, E. Tomimori, A. Gauna, R. Camargo, M. Vaisman, R. Harach, F. Munizaga, S. Corigliano, E. Pretell, H. Niepomniszcze, Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq. Bras. Endocrinol. Metabol. 53, 884–887 (2009)PubMedCrossRef
17.
R.L. Adam, R.C. Silva, F.G. Pereira, N.J. Leite, I. Lorand-Metze, K. Metze, The fractal dimension of nuclear chromatin as a prognostic factor in acute precursor B lymphoblastic leukemia. Cell. Oncol. 28, 55–59 (2006)PubMed
18.
I. Lorand-Metze, M.P. Pinheiro, E. Ribeiro, E.V. de Paula, K. Metze, Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leuk. Res. 28, 587–594 (2004)PubMedCrossRef
19.
L.A. Akslen, Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer 72, 2680–2685 (1993)PubMedCrossRef
20.
L.A. Akslen, V.A. LiVolsi, Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer 88, 1902–1908 (2000)PubMedCrossRef
21.
B. Nielsen, F. Albregtsen, W. Kildal, H.E. Danielsen, Prognostic classification of early ovarian cancer based on very low dimensionality adaptive texture feature vectors from cell nuclei from monolayers and histological sections. Anal. Cell. Pathol. 23, 75–88 (2001)PubMed
22.
S. Baheerathan, F. Albregtsen, H.E. Danielsen, Registration of serial sections of mouse liver cell nuclei. J. Microsc. 192, 37–53 (1998)PubMedCrossRef
23.
K. Metze, R.L. Adam, R.C. Ferreira, Robust variables in texture analysis. Pathology 42, 609–610 (2010). author reply 10–1PubMedCrossRef
24.
K. Metze, R.C. Ferreira, R.L. Adam, N.J. Leite, L.S. Ward, P.S. de Matos, Chromatin texture is size dependent in follicular adenomas but not in hyperplastic nodules of the thyroid. World. J. Surg. 32, 2744–2746 (2008)PubMedCrossRef
25.
B. Nielsen, F. Albregtsen, H.E. Danielsen, The use of fractal features from the periphery of cell nuclei as a classification tool. Anal. Cell. Pathol. 19, 21–37 (1999)PubMed
26.
B. Nielsen, F. Albregtsen, H.E. Danielsen, Statistical nuclear texture analysis in cancer research: a review of methods and applications. Crit. Rev. Oncog. 14, 89–164 (2008)PubMedCrossRef
27.
A. Toniato, I. Boschin, D. Casara, R. Mazzarotto, D. Rubello, M. Pelizzo, Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann. Surg. Oncol. 15, 1518–1522 (2008)PubMedCrossRef
28.
T. Nagashima, M. Sakakibara, Y. Nakatani, M. Miyazaki, Preoperative cytologic morphometry may assist in predicting patient outcome after surgery in papillary thyroid cancer. Anal. Quant. Cytol. Histol. 30, 231–236 (2008)PubMed
29.
K. Metze, R.L. Adam, Comments on the paper “c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors”. Braz. J. Med. Biol. Res. 38, 141–143 (2005). discussion 4–5PubMedCrossRef
Metadata
Title
Chromatin changes in papillary thyroid carcinomas may predict patient outcome
Authors
R. C. Ferreira
L. L. Cunha
P. S. Matos
R. L. Adam
F. Soares
J. Vassallo
L. S. Ward
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 3/2013
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-012-0116-2

Other articles of this Issue 3/2013

Cellular Oncology 3/2013 Go to the issue

Original Paper

ERM/Rho protein expression in ductal breast cancer: a 15 year follow-up

Original Paper

Tumor protein D54 is a negative regulator of extracellular matrix-dependent migration and attachment in oral squamous cell carcinoma-derived cell lines

Original Paper

Identification of a novel antagonist of the ErbB1 receptor capable of inhibiting migration of human glioblastoma cells

Original Paper

Composite fatty acid ether amides suppress growth of liver cancer cells in vitro and in an in vivo allograft mouse model

Original Paper

Multiple splice variants of EWSR1-ETS fusion transcripts co-existing in the Ewing sarcoma family of tumors

Original Paper

Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits